Login
$MCRB
$1.80 -$0.18 (9.09%) Close

Company Executives

Officer Age In this role Joined 2025 pay Source
Richard N. Kender Also a director
See Remarks
Title from the Form 4 dated Jul 8, 2026
70 Not stated Not stated Not reported
Matthew Henn
See Remarks
Title from the Form 4 dated Aug 15, 2026
51 Not stated 2012 $1,014,347
Kelly Brady
See Remarks
Title from the Form 4 dated Aug 15, 2026
42 Not stated 2018 Not reported
Thomas J. DesRosier
See Remarks
Title from the Form 4 dated Aug 15, 2026
71 Not stated Not stated $1,136,023
Marella Thorell
See Remarks
Title from the Form 4 dated Jul 8, 2026
59 Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
1 of 3
stated in the proxy; 5 not stated
Average tenure
7.4 years
from year joined
CEO also chairs the board
Yes
Richard N. Kender
Director Age On board Independent Committees Other public boards 2025 pay Source
Richard N. Kender
70 2014
12 years
Not independent None stated None stated $123,375
Stephen A. Berenson
65 2019
7 years
Not stated None stated None stated $168,985
Dennis A. Ausiello, M.D.
80 2015
11 years
Not stated None stated Alnylam Pharmaceuticals $131,688
Willard H. Dere, M.D.
72 2017
9 years
Not stated None stated BioMarin Pharmaceutical, Inc., Metagenomi, Inc. $113,375
Eric D. Shaff
50 2019
7 years
Not independent None stated None stated Not stated
Kurt C. Graves
58 2015
11 years
Not stated None stated None stated $88,375
Robert Rosiello
68 2025
1 year
Independent None stated SANA Biotechnology $147,115
Hans-Juergen Woerle, M.D., Ph.D.
60 2025
1 year
Not stated None stated None stated $132,362

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 27, 2026
SPN
wholly-owned subsidiary of Nestlé
Amount not stated
2024

Sale of the VOWST Business to SPN under the Asset Purchase Agreement, with cash payment, installment payments and milestone payments.

With Seres (the Company) Open in proxy
Nestlé Enterprises S.A. (NESA)
affiliate of SPN
Amount not stated
2024

Transition Services Agreement under which Seres provided manufacturing and administrative transition services to NESA.

With Seres (the Company) Open in proxy
SPN
Amount not stated
2024

Cross-License Agreement granting SPN patent and know-how licenses in connection with the Closing.

With Seres (the Company) Open in proxy
SPN
$15 million
2024

Securities Purchase Agreement under which SPN purchased 14,285,715 shares of Seres Common Stock.

With Seres (the Company) Open in proxy
SPN
Amount not stated
2024

Employee Support Agreement under which certain Seres employees provided services to SPN and SPN reimbursed Seres costs.

With Seres (the Company) Open in proxy
Executive officers
our executive officers
Amount not stated

Employment agreements with executive officers.

Directors and executive officers
our directors and executive officers
Amount not stated

Indemnification agreements with each director and executive officer.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support